Gary Titus, Director at ImmunoCellular Therapeutics, Ltd. (IMUC), bought 18,000 shares at $0.78 ($14K) on 2013-12-20, disclosed to the SEC on 2013-12-20.
Open-market purchase of $14k IMUC by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.78 | 100 | $78 | 0.6% |
| 2 | $0.78 | 17,900 | $14K | 99.4% |
| Total | $0.78 avg | 18,000 | $14K | 100% |
| Filing → |
| SCLN | BUY | 2012-04-04 | $3K | — | Filing → |
| SCLN | BUY | 2011-08-18 | $5K | — | Filing → |
| SCLN | BUY | 2011-06-16 | $12K | — | Filing → |